tbuckley/cabot-search huggingface dataset:
THE STATE OF THE BLOOD VESSELS OE THE EACE IN ROSACEA—II.
Authors: Peter Borrie
Journal: British Journal of Dermatology (1955)

Journal Article THE STATE OF THE BLOOD VESSELS OE THE EACE IN ROSACEA—II. Get access PETER BORRIE, M.A., M.D., M.R.C.P. PETER BORRIE, M.A., M.D., M.R.C.P. Dermatologist, Moorfields Westminster and Central Eye Hospitals, London Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 67, Issue 2, 1 February 1955, Pages 73–75, https://doi.org/10.1111/j.1365-2133.1955.tb12690.x Published: 01 February 1955
Comprehensive genomic profiling of advanced colorectal carcinoma in the course of clinical care to identify <i>KRAS</i> insertions not detected by focused molecular testing.
Authors: Andrew Rankin, Alexa Betzig Schrock, Julia Andrea Elvin, Juliann Chmielecki, Rachel Erlich, Deborah Morosini, Garrett Michael Frampton, Axel Grothey, Alan Rosenblum, Jose A. Bufill, Derek A. Helton, Judy Sequeria, Thomas J. George, Samuel Jacob Klempner, Jeffrey S. Ross, Phil Stephens, Vincent A. Miller, Siraj Mahamed Ali
Journal: Journal of Clinical Oncology (2016)

497 Background: As activating RAS mutations have been shown to predict lack of benefit from anti-EGFR therapies in advanced CRC, NCCN guidelines recommend testing for KRAS exon 2 and non-exon 2 mutations; however, these alterations are thought to explain only a subset of de novo resistance to targeted therapy. In a large set of CRC assayed with comprehensive genomic profiling (CGP) in the course of clinical care, we assessed the frequency of less common KRAS short insertions that may predict failure of anti-EGFR therapy. Methods: 4,422 CRC cases were assayed with CGP performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of &gt; 650X for at least 236 cancer-related genes plus 47 introns from 19 genes frequently rearranged in cancer. All classes of genomic alterations (GA) were identified, including base pair substitutions, insertions/deletions, copy number alterations, and rearrangements. Pertinent available prior molecular testing results and clinical history was reviewed for selected cases. Results: Out of 4,422 CRC cases analyzed, KRAS short variants were identified in 50.9% of cases. A majority of cases contained a KRAS alteration at either codon G12 (35.5%) or G13 (9.1%), while alterations at codons Q61 or A146 were identified in 2.2% and 3.1% of cases, respectively. KRAS insertions were identified in 8 ( &lt; 0.5%) cases. All KRAS insertions identified fell within codons 9-13, and 6/8 cases harbored V9_G10 insertions. Out of 6 patients with prior KRAS testing results available, 5 (83%) were negative by previous testing. Conclusions: CGP identifies KRAS insertions within or adjacent to hotspot regions in CRC cases which have previously tested negative for KRAS mutations. Given the importance of KRAS alterations in predicting lack of response to anti-EGFR therapies in CRC, accurate detection of these alterations in the course of clinical care is essential for effective treatment. CGP offers the possibility of identifying KRAS insertions that may impact efficacy of anti-EGFR targeted therapy and should be considered when previous focused testing for KRAS mutations is negative.
AB1155 Self-Reported Rheumatic Diseases and Early Retirement in Portugal – Results from the Portuguese Epidemiology Study on Rheumatic Diseases (Epireumapt)
Authors: P.A. Laires, H. Canhão, M. Gouveia, A. Rodrigues, N. Gouveia, J. Branco
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Chronic diseases and in particular rheumatic diseases (RD) may lead to early retirement, generating substantial costs to society. <h3>Objectives</h3> We aim to examine the association between self-reported RD and early retirement by using large real-world observational data. <h3>Methods</h3> EpiReumaPt was a national, cross-sectional, population-based study conducted from September 2011 to December 2013. 10,661 inhabitants were randomly surveyed in order to capture and characterize all cases of RD within a representative sample of the Portuguese population, which were stratified by administrative territorial units (NUTSII). In this analysis we used all participants aged between 50 and 65 years old, near the official retirement age (N=2,792; females: 1,727). The association of self-reported RD and early retirement was tested using individual level logistic regression. All estimates were computed as weighted proportions, in order to take into account the sampling. <h3>Results</h3> 29.9% of the Portuguese population with ages between 50 and 64 years old were officially retired. Among these, 43.2% were retired due to ill-health, which in turn about a third (30.4%) was specifically due to RD. Thus, 13.1% of all retirees self-reported RD as the main reason for early retirement. More than a third (34.2%; females: 46.3%) of all study population self-reported RD, being also more likely to self-report other main chronic disease (OR: 3.4; CI: 2.53-4.65; <i>p</i>&lt;0.001). 35.2% of RD respondents were retired versus 27.2% of those non-RD (<i>p</i>=0.025). Prevalence of self-reported RD seems to be associated with early retirement (unadjusted OR: 1.45; CI: 1.05-2.01; <i>p</i>=0.025). Some other characteristics are also associated with early retirement, in particular older age, male gender and presence of other chronic diseases. RD association tends to be independently associated with early retirement (adjusted OR: 1.41; CI: 1.03-1.95; <i>p</i>=0.031). <h3>Conclusions</h3> These results are in line with previous data from the National Health Survey conducted in Portugal nearly a decade ago and confirms the impact that self-reported RD still have on early retirement. Nevertheless, further analysis should be done in order to analyze clinically confirmed RD and to address the different RD and its relationship with early retirement. <h3>Disclosure of Interest</h3> None declared
AB0299 Patient Reported Outcomes Correlated with the Concentrations of 3-Hydroxybutyrate but not Lactate in Patients with Early Untreated Rheumatoid Arthritis:
Authors: L. Arstila, A. Kononoff, H. Kautiainen, P. Elfving, E. Savolainen, E. Savolainen, H. Niinisalo, O. Kaipiainen-Seppänen
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Patients with rheumatoid arthritis have a higher energy expenditure than healthy controls. Released cytokines have thermogenic effect, which initially increases the metabolic rate. Insulin resistance is also increased in inflammatory conditions like RA. <h3>Objectives</h3> To investigate relationship between serum lactate and 3-hydroxybutyrate and patient reported outcomes: general health (GH,VAS) and pain (VAS), among patients with newly diagnosed rheumatoid arthritis (RA) in a population based cohort. <h3>Methods</h3> For quantification of lactate and 3-hydroxybutyrate serum nuclear magnetic resonance platform operating at 500 MHz was used in native serum samples from patients with RA participating in Northern Savo 2010 Study. Age-and BMI-adjusted correlation between lactate and 3-hydroxybutyrate with GH and pain were counted. The 95% confidence intervals for the correlations were obtained by bias-corrected bootstrapping (5,000 replications). <h3>Results</h3> Serum samples from 63 patients, 34 females and 29 males with RA satisfying the ACR/Eular 2010 classification criteria were studied. The mean age (SD) of patients was 59.1 (12.0) years and the BMI 27.3 (5.4) kg/m<sup>2</sup>. 69.8% had anti-CCP antibodies. The mean DAS28 was 4.4 (1.3), GH 52.7 (25.7), pain 56.4 (29.1), HAQ 0.70 (0.65), and GP 1.62 (0.29) mmol/L. The concentrations of lactate and 3-hydroxybutyrate were 1.46±0.27 mmol/L and 0.178±0.12 mmol/l, respectively. Age- and BMI-adjusted correlations for the concentrations of lactate and 3-hydroxybutyrate with GH and pain are shown in table. There were either no correlation between the concentration of lactate and CRP, or 3-hydroxybutyrate and CRP. <h3>Conclusions</h3> In untreated RA GH correlated positively with 3-hydroxybutyrate reflecting adverse influence of fatty acid metabolism induced ketogenesis on patients9 well-being. The finding also displays insulin resistance associated with RA. <h3>References</h3> Svenson KLG, et al. Metabolism 1987;36:940-3. Soininen P et al. Analyst 2009;134:1781-5. <h3>Disclosure of Interest</h3> None declared
THE ETIOLOGY OF NEPHRITIS
Authors: J M HAYMAN
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Highly Photostable Hyperbranched Polyglycerol‐Based NIR Fluorescence Nanoplatform for Mitochondria‐Specific Cell Imaging
Authors: Chunhong Dong, Zhongyun Liu, Junqing Liu, Changzhu Wu, Falko Neumann, Hanjie Wang, Monika Schäfer‐Korting, Burkhard Kleuser, Jin Chang, Wenzhong Li, Nan Ma, Rainer Haag
Journal: Advanced Healthcare Materials (2016)

Considering the critical role of mitochondria in the life and death of cells, non-invasive long-term tracking of mitochondria has attracted considerable interest. However, a high-performance mitochondria-specific labeling probe with high photostability is still lacking. Herein a highly photostable hyperbranched polyglycerol (hPG)-based near-infrared (NIR) quantum dots (QDs) nanoplatform is reported for mitochondria-specific cell imaging. Comprising NIR Zn-Cu-In-S/ZnS QDs as extremely photostable fluorescent labels and alkyl chain (C12 )/triphenylphosphonium (TPP)-functionalized hPG derivatives as protective shell, the tailored QDs@hPG-C12 /TPP nanoprobe with a hydrodynamic diameter of about 65 nm exhibits NIR fluorescence, excellent biocompatibility, good stability, and mitochondria-targeted ability. Cell uptake experiments demonstrate that QDs@hPG-C12 /TPP displays a significantly enhanced uptake in HeLa cells compared to nontargeted QDs@hPG-C12 . Further co-localization study indicates that the probe selectively targets mitochondria. Importantly, compared with commercial deep-red mitochondria dyes, QDs@hPG-C12 /TPP possesses superior photostability under continuous laser irradiation, indicating great potential for long-term mitochondria labeling and tracking. Moreover, drug-loaded QDs@hPG-C12 /TPP display an enhanced tumor cell killing efficacy compared to nontargeted drugs. This work could open the door to the construction of organelle-targeted multifunctional nanoplatforms for precise diagnosis and high-efficient tumor therapy.
Quality of Life (Qol) with Lanreotide Autogel (Lan) Vs. Placebo in Patients with Enteropancreatic Neuroendocrine Tumours (Ep-Nets): Results from the Clarinet Phase III Study
Authors: P. Ruszniewski, M. Caplin, M. Pavel, J. Ćwikła, A. Phan, M. Raderer, E. Sedlackova, G. Cadiot, L. Wall, G. Rindi, A. Langley, J. Blumberg, E. Gomez-Panzani
Journal: Annals of Oncology (2014)
Radical Cystectomy and the Multidisciplinary Management of Muscle-Invasive Bladder Cancer
Authors: Edmund Charles Paul Chedgy, Peter C. Black
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Electroconvulsive therapy for iatrogenic hypothalamic-hypopituitarism (CRF-ACTH type)
Authors: F N Pitts, C W Patterson
Journal: American Journal of Psychiatry (1979)

A 41-year-old man with hypothalamic hypopituitarism (CRF-ACTH type) that persisted for 2 years after discontinuation of exogenous dexamethasone was treated with bilateral ECT for severe chronic depression. The depression improved only evanescently after 17 ECT sessions but the hypothalamic-pituitary suppression cleared completely and permanently, based on responses to four metyrapone stress tests in a 2-year follow-up period. ECT may be an effective treatment for persistent hypothalamic-pituitary suppression, even in the absence of a psychiatric disorder.
Bilateral versus unilateral electroconvulsive therapy: efficacy in melancholia
Authors: R Abrams, M A Taylor, R Faber, T O Ts'o, R A Williams, G Almy
Journal: American Journal of Psychiatry (1983)

The authors compared the therapeutic efficacy of bilateral and unilateral electroconvulsive therapy (ECT) in 51 patients with endogenous depression who were randomly assigned to bilateral (N = 24) or unilateral (N = 27) ECT. Seizures were monitored by oscilloscope. After 6 treatments blind assessment on a modified Hamilton depression scale showed an 81.1% improvement in the bilateral group compared with a 55.5% improvement in the unilateral group. Additional treatments were prescribed ad libitum by a hospital psychiatrist who was unaware of each patient's electrode placement. The unilateral group received more total treatments and were more frequently switched to bilateral ECT. These results were independent of age, severity of illness, or sedative drug administration.
AB0625 Emergency room Visits as a Risk Factor for Patients with Systemic Lupus Erythematosus: A Four-Year Retrospective Study in Japan: Table 1.
Authors: Y. Nagai, N. Yokogawa, K. Shimada, S. Sugii
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Many systemic lupus erythematosus (SLE) patients require emergency room (ER) visits because of flares and other complications. Distinguishing between flares and complications such as infections in the emergency ward is crucial to timely implementation of the required treatment, but sometimes poses a challenge for primary care and emergency physicians alike, resulting in delays in diagnosis and intervention. <h3>Objectives</h3> The aim of this study is to describe the characteristics of SLE patients who visit the ER, and to determine the proportion of ER visits due to SLE flares with the ultimate aim of detecting the risk factors for ER visits using multivariate logistic analysis. <h3>Methods</h3> A four-year retrospective study was performed at Tokyo Metropolitan Tama Medical Center using patients9 electronic medical records. All records of emergency room visits by SLE patients from April, 2008 to March, 2012 were extracted from the data. <h3>Results</h3> In total, 269 events were identified in 117 patients. Of these events, 91 (33.8%) were cases of infection, 32 (11.9%) of orthopedic problems and gastrointestinal disease, 31 (11.5%) of neurological disease, and 25 (9.3%) of cardiovascular events. Twenty four events (8.9%) were due to SLE flares, of which 10 (41.7%) were cases of neuropsychiatric lupus including disturbances in consciousness, aseptic meningitis, seizure, and visual field abnormality. The "ER user group" and "ER non-user group" comprised 117 and 88 patients, respectively. The dosage of glucocorticoids (prednisolone equivalent, 9.09±0.63mg, 5.36±0.73mg), intervention by psychiatrists (17/117 (14.5%), 3/88 (3.4%)), presence of neuropsychiatric lupus (23/117 (19.7%), 6/88 (6.8%)) and presence of lupus nephritis (48/117 (41.2%), 22/88 (25.0%)) were higher among the ER user group than the ER non-user group (p&lt;0.05). As a result of multivariate logistic analysis, higher glucocorticoid dosage, duration of disease, and neuropsychiatric lupus were found to be risk factors for ER visits. <h3>Conclusions</h3> Among SLE patients, infection was the principal reason for visiting the emergency room. ER visits due to SLE flares comprised only 8.9% of the total. Multivariate logistic analysis demonstrated that higher glucocorticoid dosage, duration of disease, and neuropsychiatric lupus comprised risk factors for ER visits. <h3>Disclosure of Interest</h3> None declared
Dexamethasone suppression test and mood response to methylphenidate in primary depression
Authors: P Brown, P Brawley
Journal: American Journal of Psychiatry (1983)

Thirty-four patients who met Research Diagnostic Criteria for the diagnosis of major depressive disorder, primary subtype, were given the dexamethasone suppression test (DST) and a methylphenidate challenge. The two tests divided the patients along the following lines: One group did not suppress cortisol and failed to respond to methylphenidate, while the other group did suppress cortisol and had a positive mood response to methylphenidate. In an open clinical trial, the former group responded preferentially to amitriptyline and the latter group responded preferentially to imipramine.
Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage
Authors: Adnan I. Qureshi, Yuko Y. Palesch, William G. Barsan, Daniel F. Hanley, Chung Y. Hsu, Renee L. Martin, Claudia S. Moy, Robert Silbergleit, Thorsten Steiner, Jose I. Suarez, Kazunori Toyoda, Yongjun Wang, Haruko Yamamoto, Byung-Woo Yoon
Journal: New England Journal of Medicine (2016)

Limited data are available to guide the choice of a target for the systolic blood-pressure level when treating acute hypertensive response in patients with intracerebral hemorrhage.We randomly assigned eligible participants with intracerebral hemorrhage (volume, <60 cm(3)) and a Glasgow Coma Scale (GCS) score of 5 or more (on a scale from 3 to 15, with lower scores indicating worse condition) to a systolic blood-pressure target of 110 to 139 mm Hg (intensive treatment) or a target of 140 to 179 mm Hg (standard treatment) in order to test the superiority of intensive reduction of systolic blood pressure to standard reduction; intravenous nicardipine to lower blood pressure was administered within 4.5 hours after symptom onset. The primary outcome was death or disability (modified Rankin scale score of 4 to 6, on a scale ranging from 0 [no symptoms] to 6 [death]) at 3 months after randomization, as ascertained by an investigator who was unaware of the treatment assignments.Among 1000 participants with a mean (±SD) systolic blood pressure of 200.6±27.0 mm Hg at baseline, 500 were assigned to intensive treatment and 500 to standard treatment. The mean age of the patients was 61.9 years, and 56.2% were Asian. Enrollment was stopped because of futility after a prespecified interim analysis. The primary outcome of death or disability was observed in 38.7% of the participants (186 of 481) in the intensive-treatment group and in 37.7% (181 of 480) in the standard-treatment group (relative risk, 1.04; 95% confidence interval, 0.85 to 1.27; analysis was adjusted for age, initial GCS score, and presence or absence of intraventricular hemorrhage). Serious adverse events occurring within 72 hours after randomization that were considered by the site investigator to be related to treatment were reported in 1.6% of the patients in the intensive-treatment group and in 1.2% of those in the standard-treatment group. The rate of renal adverse events within 7 days after randomization was significantly higher in the intensive-treatment group than in the standard-treatment group (9.0% vs. 4.0%, P=0.002).The treatment of participants with intracerebral hemorrhage to achieve a target systolic blood pressure of 110 to 139 mm Hg did not result in a lower rate of death or disability than standard reduction to a target of 140 to 179 mm Hg. (Funded by the National Institute of Neurological Disorders and Stroke and the National Cerebral and Cardiovascular Center; ATACH-2 ClinicalTrials.gov number, NCT01176565 .).
RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction
Authors: Hendrik B. Sager, Partha Dutta, James E. Dahlman, Maarten Hulsmans, Gabriel Courties, Yuan Sun, Timo Heidt, Claudio Vinegoni, Anna Borodovsky, Kevin Fitzgerald, Gregory R. Wojtkiewicz, Yoshiko Iwamoto, Benoit Tricot, Omar F. Khan, Kevin J. Kauffman, Yiping Xing, Taylor E. Shaw, Peter Libby, Robert Langer, Ralph Weissleder, Filip K. Swirski, Daniel G. Anderson, Matthias Nahrendorf
Journal: Science Translational Medicine (2016)

Myocardial infarction (MI) leads to a systemic surge of vascular inflammation in mice and humans, resulting in secondary ischemic complications and high mortality. We show that, in ApoE(-/-) mice with coronary ligation, increased sympathetic tone up-regulates not only hematopoietic leukocyte production but also plaque endothelial expression of adhesion molecules. To counteract the resulting arterial leukocyte recruitment, we developed nanoparticle-based RNA interference (RNAi) that effectively silences five key adhesion molecules. Simultaneously encapsulating small interfering RNA (siRNA)-targeting intercellular cell adhesion molecules 1 and 2 (Icam1 and Icam2), vascular cell adhesion molecule 1 (Vcam1), and E- and P-selectins (Sele and Selp) into polymeric endothelial-avid nanoparticles reduced post-MI neutrophil and monocyte recruitment into atherosclerotic lesions and decreased matrix-degrading plaque protease activity. Five-gene combination RNAi also curtailed leukocyte recruitment to ischemic myocardium. Therefore, targeted multigene silencing may prevent complications after acute MI.